Rocket Pharmaceuticals (NASDAQ:RCKTW) Stock Price Up 36.9%

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) shares rose 36.9% on Friday . The stock traded as high as $0.13 and last traded at $0.12. Approximately 2,500 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 25,524 shares. The stock had previously closed at $0.09.

Rocket Pharmaceuticals Stock Up 36.9 %

The company has a fifty day simple moving average of $0.14 and a two-hundred day simple moving average of $0.17.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Boothbay Fund Management LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 2nd quarter worth $4,773,000. JPMorgan Chase & Co. acquired a new stake in shares of Rocket Pharmaceuticals during the 1st quarter worth $27,000. Fort Baker Capital Management LP acquired a new stake in shares of Rocket Pharmaceuticals during the 1st quarter worth $49,000. RTW Investments LP acquired a new stake in shares of Rocket Pharmaceuticals during the 1st quarter worth $38,000. Finally, Sio Capital Management LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 1st quarter worth $65,000.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.